Biologics CDMO Market, By Type (Mammalian, Non-Mammalian), By Product Type (Biologics (Recombinant Proteins, Vaccines, Monoclonal, Antisense & Molecular Therapy, and Other Biologics) and Biosimilars), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

At a compound annual growth rate (CAGR) of 11.80%, the biologics CDMO market is expected to reach US$ 55 billion by 2034 from its 2024 valuation of US$ 18 billion.

In inflammatory diseases like arthritis, biologics have become potent medications that reduce inflammation, protecting joints and other organs from harm. Pharmaceutical companies can use the biological, medical product development, and manufacturing services provided by Biologics CDMO (contract development and manufacturing organization).

The aging population and rising chronic illnesses have fueled market expansion. Biologics CDMO market growth is anticipated to be lucrative due to the growing demand for novel therapies and the need for pharmaceutical companies to invest significant capital in innovative and advanced technologies.